Comment
doi: 10.1016/S1470-2045(12)70591-0.
Epub 2013 Jan 8.
Prostate cancer therapy: going forwards by going backwards
Affiliations
- PMID: 23306099
- DOI: 10.1016/S1470-2045(12)70591-0
Item in Clipboard
Comment
Prostate cancer therapy: going forwards by going backwards
Lancet Oncol.
2013 Feb.
No abstract available
Comment on
-
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
Similar articles
-
Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.J Urol. 2013 Dec;190(6):2094. doi: 10.1016/j.juro.2013.08.104. Epub 2013 Sep 7. J Urol. 2013. PMID: 24209521 No abstract available.
-
CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192. Epub 2015 Nov 10. Nat Rev Clin Oncol. 2015. PMID: 26552950 No abstract available.
-
Prolonging survival in prostate cancer: chemotherapy will have an important role.BJU Int. 2005 Jul;96(1):2-3. doi: 10.1111/j.1464-410X.2005.05554.x. BJU Int. 2005. PMID: 15963108 No abstract available.
-
Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.BJU Int. 2017 Dec;120(6):751-754. doi: 10.1111/bju.13990. Epub 2017 Sep 5. BJU Int. 2017. PMID: 28834013 Review. No abstract available.
-
Chemotherapy for metastatic castrate-sensitive prostate cancer.Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44. doi: 10.1038/pcan.2016.10. Epub 2016 Mar 15. Prostate Cancer Prostatic Dis. 2016. PMID: 26976365 Review.
Cited by
-
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14. Med Oncol. 2016. PMID: 27300548 Free PMC article.
-
Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.Asian J Androl. 2017 Mar-Apr;19(2):178-183. doi: 10.4103/1008-682X.174856. Asian J Androl. 2017. PMID: 26975487 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
